NASDAQ: CRDF
Cardiff Oncology Inc Stock Ownership - Who owns Cardiff Oncology?

Insider buying vs selling

Have Cardiff Oncology Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Gary W. PaceDirector2025-07-30275,000$2.45
$673.75kBuy
Gary W. PaceDirector2025-07-3015,000$2.45
$36.75kBuy

1 of 1

CRDF insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CRDF insiders and whales buy or sell their stock.

CRDF Shareholders

What type of owners hold Cardiff Oncology Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Robert Merrill Hunter7.41%5,065,004$7.80MInsider
Blackrock Inc5.82%3,981,387$6.13MInstitution
Ra Capital Management LP4.81%3,290,000$5.07MInsider
Gary W. Pace4.57%3,124,113$4.81MInsider
Bridger Management LLC4.34%2,968,115$4.57MInsider
Vanguard Capital Management LLC4.18%2,855,966$4.40MInstitution
Laurion Capital Management LP3.87%2,646,738$4.08MInstitution
Pfizer Inc3.53%2,411,575$3.71MInstitution
Acorn Capital Advisors LLC2.58%1,762,084$2.71MInstitution
Geode Capital Management LLC2.34%1,599,663$2.46MInstitution

1 of 3

CRDF vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CRDF35.96%25.65%Net Buying
CBUS28.69%64.69%Net BuyingNet Selling
VANI3.40%96.60%Net BuyingNet Buying
ATHE0.00%0.17%
BDTX65.60%34.40%Net BuyingNet Buying

Cardiff Oncology Stock Ownership FAQ

Who owns Cardiff Oncology?

Cardiff Oncology (NASDAQ: CRDF) is owned by 35.96% institutional shareholders, 25.65% Cardiff Oncology insiders, and 38.39% retail investors. Robert Merrill Hunter is the largest individual Cardiff Oncology shareholder, owning 5.07M shares representing 7.41% of the company. Robert Merrill Hunter's Cardiff Oncology shares are currently valued at $7.19M.

If you're new to stock investing, here's how to buy Cardiff Oncology stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.